Therapeutic Solutions International
Announces CTE Optimized NeuroStilbene
Formulation
OCEANSIDE, CA
-- October
25, 2018 --
InvestorsHub NewsWire -- Therapeutics
Solutions International, Inc., (OTC Markets:
TSOI)
announced
today a newly optimized
formulation of NeuroStilbene
for
intranasal delivery. The company has
previously filed intellectual property and generated data
demonstrating suppression of neuronal cell death and reduction of
neuroinflammation in models of Chronic Traumatic Encephalopathy
(CTE). The optimized formulation developed, possesses
an enhanced delivery ability and increased concentration of
the active ingredient, pterostilbene.
Chronic Traumatic
Encephalopathy (CTE) is a
progressive degenerative disease of the brain found in people with
a history of repetitive brain trauma such as
athletes
and
military veterans. The trauma may include symptomatic
concussions as well as asymptomatic
sub-concussive hits to
the head that do not cause symptoms. Common
symptoms of CTE
in the
early stages of the condition include impulse control problems,
aggression, depression, and paranoia. As the disease progresses,
some patients may experience problems with thinking and memory,
including memory loss, confusion, impaired judgment, and eventually
progresses to dementia.
"In an ideal setting,
clinical implementation of NeuroStilbene requires delivery of the
highest amount of pterostilbene possible in the most effective
manner,"
said Dr. James
Veltmeyer, Chief Medical Officer of Therapeutic Solutions
International. "The new formulation
utilizes nanoparticle technology, combined with proprietary
chemistry to ensure optimal concentrations of the
active agent are found in the central nervous system to prevent
pathology associated with neuronal injury."
"The newly formulated
NeuroStilbene is 6.6x more concentrated than our previous version
which contained 30mg of nanoparticle pterostilbene per milliliter
of the nanoemulsion. This new formulation contains 200mg per
milliliter. This
means we
can deliver six times
more
pterostilbene intranasally per application than current
formulation that is now
increased
from 3mg
to 20mg per pump application"
said Timothy Dixon,
President, and CEO of TSOI.
"We
are eager to start receiving feedback from our collaborators on the
effects of this new formulation".
About Therapeutic Solutions International,
Inc.
Therapeutic Solutions
International is focused on immune modulation for the treatment of
several specific diseases. Immune modulation refers to the ability
to upregulate (make more active) or downregulate (make less active)
one's immune system. The Company's corporate website is
www.therapeuticsolutionsint.com.
These statements have
not been evaluated by the Food and Drug Administration. These
products are not intended to diagnose, treat, cure, or prevent any
disease.
Safe Harbor
Statement
This release contains
forward-looking statements that are based upon current expectations
or beliefs, as well as a number of assumptions about future events.
Although we believe that the expectations reflected in the
forward-looking statements and the assumptions upon which they are
based are reasonable, we can give no assurance that such
expectations and assumptions will prove to have been correct.
Forward-looking statements are generally identifiable by the use of
words like "may," "will," "should," "could," "expect,"
"anticipate," "estimate," "believe," "intend," or "project" or the
negative of these words or other variations on these words or
comparable terminology. The reader is cautioned not to put undue
reliance on these forward-looking statements, as these statements
are subject to numerous risk factors as set forth in our SEC
filings. To the extent that statements in this press release are
not strictly historical, including statements as to product launch
timing, revenue projections, business strategy, outlook,
objectives, future milestones, plans, intentions, goals, future
collaboration agreements, or otherwise as to future events, such
statements are forward-looking, and are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. The forward-looking statements contained in this release
are subject to certain risks and uncertainties that could cause
actual results to differ materially from the statements
made.
CONTACT
INFORMATION